Page 1

Siemens Healthineers continues to post strong growth - outlook raised again Erlangen , May 3 , 2021 - Siemens Healthineers AG today announced its results for the second quarter of fiscal year 2021 that ended March 31 , 2021 . Q2 Fiscal Year 2021 • • • Very good revenue development continued in the second quarter with 12.9 % comparable growth from the prior - year quarter Equipment book - to - bill ratio at 1.08 Development in Diagnostics again outstanding with 29.1 % comparable revenue growth – continued high demand for rapid COVID - 19 antigen tests Strong comparable revenue growth of 7.4 % in Imaging ; Advanced Therapies with comparable growth of 2.0 % Adjusted EBIT margin at 16.8 % • Adjusted basic earnings per share at € 0.44 • Free cash flow of € 359 million significantly above comparatively weak prior - year figure Updated Outlook for Fiscal Year 2021 • Varian acquisition successfully completed on April 15 , 2021 • Comparable revenue growth between 14 % and 17 % expected ( previously 8 % to 12 % ) Adjusted basic earnings per share between € 1.90 and € 2.05 ( previously € 1.63 to € 1.82 ) Bernd Montag , CEO of Siemens Healthineers AG : >> The Siemens Healthineers team has done an outstanding job during the past months . While we have further improved our op- erational performance and have once again made a valuable contribution to cope with this historical crisis , we have at the same time managed to successfully complete the largest transaction in our history . Together with Varian , we are making a leap in cancer care and a leap in our impact on global healthcare . With our even more comprehensive portfolio , we are addressing many of the most important diseases . Against the backdrop of continued strong business development in the second quarter and the transformative merger with Varian , we have again raised our outlook for the current fiscal year . <<